A recent trial found that the Bruton tyrosine kinase inhibitor, ibrutinib (Imbruvica), increased progression-free survival in older patients with chronic lymphocytic leukemia compared to standard treatment.
The American Society of Clinical Oncology recommends stricter oversight and regulations for handling hazardous drugs.
The FDA Oncologic Drugs Advisory Committee did not approve selinexor (Karyopharm Therapeutics) for patients with relapsed-refractory multiple myeloma.
Recent research shows that prophylactic treatment of febrile neutropenia can benefit patients receiving chemotherapy, though experts are calling for improvements in risk modeling to determine who would benefit most from prophylaxis.
What risks do patients with breast cancer face when their treatment is delayed? Experts review the evidence and highlight key factors to consider when establishing a care pathway.
Clin Onc News Report is brought to MedPage Today readers by our friends at Clinical Oncology News, a McMahon Group title. Registration (free) may be required for some content.